Healthcare Companies Report Financial Results, Scheduled Presentations, Marketing Clearance and Recognitions - Research Report on Air Methods, NeuroMetrix, Quintiles, Auxilium, and Cynosure
Editor Note: For more information about this release, please scroll to bottom.
NEW YORK, November 12, 2013 /PRNewswire/ --
Today, Analysts' Corner announced new research reports highlighting Air Methods Corp. (NASDAQ: AIRM), NeuroMetrix Inc. (NASDAQ: NURO), Quintiles Transnational Holdings Inc. (NYSE: Q), Auxilium Pharmaceuticals Inc. (NASDAQ: AUXL), and Cynosure, Inc. (NASDAQ: CYNO). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Air Methods Corp. Research Report
On November 7, 2013, Air Methods Corp. (Air Methods) released its Q3 2013 financial results. Total revenues were up by 14.1% YoY to $252.4 million during the quarter. Net income was $35.6 million or $0.91 per diluted share in Q3 2013, compared to $27.8 million or $0.71 per diluted share in Q3 2012. Commenting on the results, Aaron Todd, CEO of Air Methods, stated, "Our third quarter reflects a return to growth in earnings fueled by strong growth in net revenue per patient transport and more moderate maintenance expenditures as anticipated. Our growth in net revenue per transport reflects more stable year-over-year payer mix and has been realized while reducing our days' sales outstanding, which decreased from 108 days as of September 30, 2012 and 99 days as of June 30, 2013, to 92 days as of September 30, 2013 based on 90-day annualized net revenue. We are also very pleased that our investment in Sundance and the tourism sector continues to generate accretive financial results, in line with our initial expectations." The Full Research Report on Air Methods Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/ff38_AIRM]
--
NeuroMetrix Inc. Research Report
On November 7, 2013, NeuroMetrix Inc. (NeuroMetrix) announced that Shai N. Gozani, M.D., Ph. D., President and CEO of the Company, is scheduled to present at the Canaccord Genuity Medical Technology & Diagnostics Forum, at the Westin Grand Central, New York, on November 14, 2013 at 8:00 am EDT. NeuroMetrix informed that in his presentation, Dr. Gozani will provide an update on the Company's business activities with emphasis on its SENSUS™ pain management system for relief of chronic intractable pain, including pain associated with diabetic neuropathy. The Full Research Report on NeuroMetrix Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/b5b2_NURO]
--
Quintiles Transnational Holdings Inc. Research Report
On November 6, 2013, Quintiles Transnational Holdings Inc. (Quintiles) announced that the Healthcare Businesswomen's Association (HBA) has honored the Company's Women Inspired Network (WIN) with the 2013 HBA ACE Award. According to the Company, it will receive the ACE Award at the 2013 HBA Leadership Conference, to be held in Boston, Massachusetts, on November 14, 2013. Commenting on the achievement, Tom Pike, CEO of the Company, stated, "Winning the 2013 HBA ACE Award validates Quintiles' significant efforts to foster the development of women leaders throughout our organization and the industry. WIN is a very important part of the fabric of our organization and one of the great catalysts we have internally for leadership development. Women comprise about 65% of Quintiles' population and we promote the idea that women innovate, achieve business goals and advance Quintiles' industry leadership in every job throughout the company." The Full Research Report on Quintiles Transnational Holdings Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/9f5c_Q]
--
Auxilium Pharmaceuticals Inc. Research Report
On November 6, 2013, Auxilium Pharmaceuticals Inc. (Auxilium) released its Q3 2013 financial results. On a GAAP basis, net revenues (including Actient revenues from its acquisition date, April 26, 2013) of the Company were up by 52.3% YoY to $108.1 million during the quarter. GAAP net loss in Q3 2013 was $28.9 million or $0.59 per diluted share, compared to GAAP net loss of $10.5 million or $0.21 per diluted share in Q3 3012. Commenting on the results, Adrian Adams, CEO and President of Auxilium, stated, "We are pleased with the overall momentum of the business and are delighted to deliver what we consider to be a strong third quarter of record revenues in addition to significant non-GAAP earnings per share growth." The Full Research Report on Auxilium Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/86a4_AUXL]
--
Cynosure, Inc. Research Report
On November 6, 2013, Cynosure, Inc. (Cynosure) announced that Australia's Therapeutic Goods Administration has granted marketing clearance for the PicoSure™ Picosecond Laser (PicoSure). According to the Company, PicoSure, the world's first picosecond laser for the removal of tattoos and benign pigmented lesions, was introduced in the US at the beginning of 2013 after receiving clearance from the U.S. Food and Drug Administration. Commenting on the release, Michael Davin, Cynosure's President and CEO stated, "PicoSure continues to be enthusiastically received by physicians and consumers in North America and Europe, and we are excited about the opportunity to market the product to our customers and their patients in Australia, which is a new direct sales territory for the Company." The Company informed that it has also received approval from the China Food and Drug Administration to market Smartlipo MPX™ LaserBodySculpting™ Workstation, the industry's leading laser-assisted lipolysis system designed to disrupt fat cells and tighten tissue through tissue coagulation. The Full Research Report on Cynosure, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/6e59_CYNO]
----
EDITOR NOTES:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
- For any urgent concerns or inquiries, please contact us at [email protected].
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
AnalystsCorner.com
SOURCE Analysts' Corner
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article